Stem Cells and Type I Diabetes

Published 2024-10-01

Researchers from Nankai University, China recently published results of their research on their use of autologous induced Pluripotent Stem Cells for a patient with Type I Diabetes Mellitus. Autologous cells were chemically reprogrammed into pancreatic islet cells and injected beneath the anterior rectus sheath of the abdomen. During the 1 year followup, the islet cells appear to have engrafted and have provided stable glycemic control. The patient achieved insulin independence at 75 days post implant and has maintained a time-in-target glycemic range at >98% and glycated hemoglobin at around 5%. This first-in-human case will become part of a planned broader clinical trial.